<div id="readability-page-1"><p>Arista Wealth Management LLC acquired a new stake in  Sanofi (NASDAQ:SNY - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 7,890 shares of the company's stock, valued at approximately $381,000.</p><ul><li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li></ul><p>Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Ameritas Advisory Services LLC acquired a new position in shares of  Sanofi during the 2nd quarter worth $28,000.  Accent Capital Management LLC acquired a new position in shares of  Sanofi during the 1st quarter worth $29,000.  Eastern Bank raised its holdings in shares of  Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after buying an additional 300 shares in the last quarter.  Banque Transatlantique SA acquired a new position in  Sanofi in the 1st quarter worth about $33,000.  Finally, Golden State Wealth Management LLC increased its holdings in  Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after purchasing an additional 545 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, September 2nd. Wall Street Zen upgraded Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, August 2nd. Morgan Stanley upgraded Sanofi from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and upped their target price for the company from $56.00 to $58.00 in a research report on Monday, September 8th. JPMorgan Chase &amp; Co. upgraded Sanofi from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating in a research report on Friday, August 8th. Finally, Weiss Ratings  reaffirmed a &#34;hold (c)&#34; rating on shares of Sanofi in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Sanofi presently has a consensus rating of &#34;Buy&#34; and an average price target of $62.67.</p><ul><li>Analysts Think These Stocks Could More Than Double in Value</li></ul><p><b>Read Our Latest Report on SNY</b></p><h2>Sanofi Stock Performance</h2><p>Shares of SNY opened at $50.62 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $124.30 billion, a price-to-earnings ratio of 12.17, a PEG ratio of 1.22 and a beta of 0.51. The stock has a 50 day moving average of $48.49 and a 200 day moving average of $49.63. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. </p><ul><li>Regeneron: Is It the Perfect Biotech Stock for Value and Growth?</li></ul><p>Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period last year, the company posted $1.73 earnings per share. Sanofi's revenue for the quarter was down 7.0% on a year-over-year basis.  As a group, sell-side analysts forecast that  Sanofi will post 4.36 earnings per share for the current year. </p><h2>Sanofi Company Profile</h2> (Free Report)<p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p><h2>See Also</h2><ul><li>Five stocks we like better than Sanofi</li><li>How to Calculate Retirement Income: MarketBeat’s Calculator</li><li>This AI Chip Giant Could Be the Market’s Next Big Winner</li><li>3 Small Caps With Big Return Potential</li><li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li><li>What Is WallStreetBets and What Stocks Are They Targeting?</li><li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li></ul><p><strong>Want to see what other hedge funds are holding SNY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sanofi Right Now?</h2><p>Before you consider Sanofi, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p><p>While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SNYNF

<p>Arista Wealth Management LLC acquired 7,890 shares of Sanofi (NASDAQ:SNY) in Q2, valued at approximately $381,000, according to SEC disclosures. Other institutional investors have also increased their stakes in Sanofi. Analysts have upgraded Sanofi's rating, with a consensus rating of "Buy" and an average price target of $62.67. Sanofi's stock opened at $50.62, with a market cap of $124.30 billion. The company reported $0.90 earnings per share for the last quarter, missing estimates, with revenue of $11.34 billion, down 7% year-over-year.</p>

Arista Wealth Management LLC Acquires Shares of 7,890 Sanofi $SNY